High-sensitive detection and quantitation of thyroid-stimulating hormone (TSH) from capillary/fingerstick and venepuncture whole-blood using fluorescence-based rapid lateral flow immunoassay (LFIA)
Shurbaji et al.
The finding, in our words
In 102 samples, quantitative TSH by Finecare LFIA showed strong correlation (r approximately 0.93) and excellent agreement (Cohen's kappa 0.85) with the Roche CobasPro reference; using serum, sensitivity was 90.5% and specificity 96.3% for diagnosing thyroid abnormalities, supporting fingerstick and whole-blood use for decentralised TSH testing.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Earlobe capillary microsampling of 100-250 µL found good agreement with venous draws for progesterone, concordance 0.911, and 17β-estradiol, concordance 0.919, across menstrual cycles, showing suitability for decentralised monitoring. However, participant-reported burden was not assessed, and further validation is required in elite athletes.
In 46 women under hormone monitoring at Columbia University Fertility Center, oestradiol, LH, FSH, progesterone and hCG measured on routine immunoassays from 400 to 600 microlitres of upper-arm capillary blood collected with TAP Micro Select agreed closely with paired venous results for every analyte, with correlation and concordance high throughout. It is the evidence that puts a self-collected sample inside the daily monitoring of an IVF cycle.
Lattin et al., Fertility and sterility (paywalled) · source ↗
The homeRNA capillary blood collection and stabilization platform successfully captured lipopolysaccharide-induced inflammatory gene expression profiles. These transcriptomic responses were comparable to those obtained from traditional venous blood samples stabilized with RNAlater or PAXgene, demonstrating the platform's suitability for remote transcriptomic monitoring.
Brown et al., Analytical chemistry (paywalled) · source ↗
In pregnant women at high risk of gestational diabetes, the GTT@home capillary glucose device showed a small positive bias of 0.16 mmol/L versus venous laboratory OGTT, with 79.8 per cent of results in the lowest surveillance risk zone and diagnostic classification agreement in 54 of 61 cases, suggesting it could support home OGTT in pregnancy.
The POC haemoglobin device showed moderate correlation with laboratory values but was not accurate enough for routine monitoring; however, it had a high negative predictive value at the 7 g/dL threshold, meaning it can reliably rule out severe anaemia and may help avoid unnecessary transfusions and hospital visits if confirmed in larger studies.